Blood Cancer United

Dr. Gwen Nichols explains how Orca‑T may reduce graft-versus-host disease and impact treatment decisions for certain patients with blood cancers.

Joe McDonough shares what message he hopes families hear when first facing a cancer diagnosis.

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

The author and advocate, facing leukemia for the third time in 15 years, sat down for an interview with CURE.

CURE spoke with chief medical officer Gwen Nichols and partner Suleika Jaouad about the inclusive rebranding.

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United.

The Leukemia & Lymphoma Society, a nonprofit in funding blood cancer research, patient support and advocacy, is becoming Blood Cancer United on August 28.

It’s easy to think of scientific researchers as existing in a vacuum.

Nutrition is a challenge for many patients with cancer.

Cancer is one of the most expensive medical conditions to treat in the U.S.

As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer.

Treating patients with CAR-T cell therapy Breyanzi may change the paradigm for those with relapsed or refractory mantle cell lymphoma, an expert said.

Increased awareness and support may be one of the many ways to help decrease the impact of disparities in multiple myeloma.

An FDA committee voted that the benefits of Carvykti outweigh the risks for myeloma treatment, though concerns about secondary malignancies remain.

Menin inhibitors for patients with AML have been one of many improvements within the blood cancer space this year, Lee Greenberger of the Leukemia and Lymphoma Society told CURE®.

LLS’s Investment in Leading-Edge Research Aims to Accelerate Treatment Innovation and Expand Equitable Access to Treatments to Increase the Quality of Life and Survival Rates for All Blood Cancer Patients.